FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Albers Jeffrey W. 2. Issuer Name and Ticker or Trading Symbol Blueprint Medicines Corp [ BPMC ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CEO and President
(Last)         (First)         (Middle)
C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
11/15/2021
(Street)
CAMBRIDGE, MA 02139
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/15/2021    M(1)    7500  A $1.87  195948  D   
Common Stock  11/15/2021    M(1)    22500  A $15.01  218448  D   
Common Stock  11/15/2021    S(1)    21906  D $114.73 (2) 196542  D   
Common Stock  11/15/2021    S(1)    7894  D $113.92 (3) 188648  D   
Common Stock  11/15/2021    S(1)    100  D $113.25  188548  D   
Common Stock  11/15/2021    S(1)    100  D $112.14  188448  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $1.87  11/15/2021    M (1)       7500    (4) 7/30/2024  Common Stock  7500  $0  135403  D   
Stock Option (Right to Buy)  $15.01  11/15/2021    M (1)       22500    (5) 2/3/2026  Common Stock  22500  $0  77500  D   

Explanation of Responses:
(1)  Effected pursuant to a trading plan adopted on January 11, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
(2)  The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.36 to $115.34 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
(3)  The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.41 to $114.32 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
(4)  This option was granted on July 30, 2014 and is fully vested as of the date hereof.
(5)  This option was granted on February 3, 2016 and is fully vested as of the date hereof.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Albers Jeffrey W.
C/O BLUEPRINT MEDICINES CORPORATION
45 SIDNEY STREET
CAMBRIDGE, MA 02139
X
CEO and President

Signatures
/s/ Ariel Hurley, Attorney-in-Fact 11/17/2021
**Signature of Reporting Person Date
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Blueprint Medicines Charts.